Oxidative Stress and Aberrant Cell Cycle in Alzheimer’s Disease Lymphocytes: Diagnostic Prospects
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
In Alzheimer's disease (AD), molecular changes are observed not only in patients' neurons but also in peripheral cells, such as blood lymphocytes. These include changes in the level of oxidative stress markers, mitochondria impairment, and aberrant cell cycle regulation in AD blood lymphocytes. While the concepts of early causes of AD are currently highly controversial, these findings provide support for the cell cycle hypothesis of AD pathomechanism and emphasize the systemic nature of the disease. Moreover, because of difficulties in studying dynamic processes in the human brain, lymphocytes seem to be useful for readout of AD molecular mechanisms. In addition, lymphocytes as easily accessible human cells have potential diagnostic value. We summarize current perspectives for the development of new therapeutic strategies based on oxidative stress and cell cycle dysregulation in AD, and for diagnostic methodologies involving new markers in AD lymphocytes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050
The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
Benilova, I., Karran, E., & De Strooper, B. (2012) · Nature Neuroscience · doi:10.1038/nn.3028 · Cited by 1,962
Talbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871
Grundman, M. (2004) · Archives of Neurology · doi:10.1001/archneur.61.1.59 · Cited by 972
Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease
Price, J. L., McKeel, D. W., Buckles, V. D., Roe, C. M., Xiong, C., Grundman, M., Hansen, L. A., Petersen, R. C., Parisi, J. E., Dickson, D. W., et al. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.04.002 · Cited by 661
Linking Aβ and Tau in Late-Onset Alzheimer's Disease: A Dual Pathway Hypothesis
Small, S. A., & Duff, K. (2008) · Neuron · doi:10.1016/j.neuron.2008.11.007 · Cited by 546
Bernstein, C. (2002) · Mutation Research/Reviews in Mutation Research · doi:10.1016/s1383-5742(02)00009-1 · Cited by 527
Cell cycle regulation in the postmitotic neuron: oxymoron or new biology?
Herrup, K., & Yang, Y. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2124 · Cited by 507
Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer’s disease
Yang, Y., Mufson, E. J., & Herrup, K. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-07-02557.2003 · Cited by 483
Deciphering the mechanism underlying late-onset Alzheimer disease
Krstic, D., & Knuesel, I. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.236 · Cited by 457
Reddy, P. H., Tripathi, R., Troung, Q., Tirumala, K., Reddy, T. P., Anekonda, V., Shirendeb, U. P., Calkins, M. J., Reddy, A. P., Mao, P., et al. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.10.011 · Cited by 394
Absalon, S., Kochanek, D. M., Raghavan, V., & Krichevsky, A. M. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.1327-13.2013 · Cited by 302
CHEN, Q. M., LIU, J., & MERRETT, J. B. (2000) · Biochemical Journal · doi:10.1042/bj3470543 · Cited by 280
Calcium signalling and Alzheimer's disease
Berridge, M. J. (2011) · Neurochemical Research · doi:10.1007/s11064-010-0371-4 · Cited by 167
Age-dependent rescue by simvastatin of Alzheimer’s disease cerebrovascular and memory deficits
Tong, X.-K., Lecrux, C., & Hamel, E. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0169-12.2012 · Cited by 160
Antiamyloid Therapy for Alzheimer's Disease — Are We on the Right Road?
Karran, E., & Hardy, J. (2014) · New England Journal of Medicine · doi:10.1056/nejme1313943 · Cited by 126
Sultana, R., Mecocci, P., Mangialasche, F., Cecchetti, R., Baglioni, M., & Butterfield, D. A. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-101425 · Cited by 111
Silva, A. R. T., Santos, A. C. F., Farfel, J. M., Grinberg, L. T., Ferretti, R. E. L., Campos, A. H. J. F. M., Cunha, I. W., Begnami, M. D., Rocha, R. M., Carraro, D. M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099897 · Cited by 99
The cell cycle as a therapeutic target for Alzheimer's disease
Neve, R. L., & McPhie, D. L. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.09.005 · Cited by 92
Dysfunction of the mTOR pathway is a risk factor for Alzheimer's disease
Yates, S. C., Zafar, A., Hubbard, P., Nagy, S., Durant, S., Bicknell, R., Wilcock, G., Christie, S., Esiri, M. M., Smith, A. D., et al. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-3 · Cited by 76
Sultana, R., Baglioni, M., Cecchetti, R., Cai, J., Klein, J. B., Bastiani, P., Ruggiero, C., Mecocci, P., & Butterfield, D. A. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.08.001 · Cited by 64
Mangialasche, F., Baglioni, M., Cecchetti, R., Kivipelto, M., Ruggiero, C., Piobbico, D., Kussmaul, L., Monastero, R., Brancorsini, S., & Mecocci, P. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142052 · Cited by 53
Katsel, P., Tan, W., Fam, P., Purohit, D. P., & Haroutunian, V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068361 · Cited by 52
Impairment of mitogenic activation of peripheral blood lymphocytes in Alzheimer's disease
Stieler, J. T., Lederer, C., Brückner, M. K., Wolf, H., Holzer, M., Gertz, H.-J., & Arendt, T. (2001) · Neuroreport · doi:10.1097/00001756-200112210-00023 · Cited by 43
Sanphui, P., Pramanik, S. K., Chatterjee, N., Moorthi, P., Banerji, B., & Biswas, S. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078842 · Cited by 38
Bialopiotrowicz, E., Kuzniewska, B., Kachamakova-Trojanowska, N., Barcikowska, M., Kuznicki, J., & Wojda, U. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.017 · Cited by 32
Self-citationEsteras, N., Bartolomé, F., Alquézar, C., Antequera, D., Muñoz, Ú., Carro, E., & Martín‐Requero, Á. (2012) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2012.08178.x · Cited by 30
Self-citationEsteras, N., Alquézar, C., Bermejo-Pareja, F., Bialopiotrowicz, E., Wojda, U., & Martín-Requero, Á. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.10.014 · Cited by 25
Self-citation
Cited by
Alzheimer’s disease and its treatment by different approaches: A review
Srivastava, S., Ahmad, R., & Khare, S. K. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113320 · Cited by 467
Mitochondria as Potential Targets in Alzheimer Disease Therapy: An Update
Cenini, G., & Voos, W. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00902 · Cited by 257
Oxidant/Antioxidant Imbalance in Alzheimer’s Disease: Therapeutic and Diagnostic Prospects
Wojsiat, J., Zoltowska, K. M., Laskowska-Kaszub, K., & Wojda, U. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/6435861 · Cited by 221
Self-citationCDT2‐controlled cell cycle reentry regulates the pathogenesis of Alzheimer's disease
Huang, F., Wang, M., Liu, R., Wang, J., Schadt, E., Haroutunian, V., Katsel, P., Zhang, B., & Wang, X. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.08.013 · Cited by 47
Tramutola, A., Abate, G., Lanzillotta, C., Triani, F., Barone, E., Iavarone, F., Vincenzoni, F., Castagnola, M., Marziano, M., Memo, M., et al. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.10.414 · Cited by 26
Metadata
- Authors
- Wojsiat, J., Prandelli, C., Laskowska-Kaszub, K., Martín-Requero, A., & Wojda, U.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2015-05-30
- Volume
- 46
- Issue
- 2
- Pages
- 329-350
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1668690894
- Cited by
- 54
- References
- 28
- FWCI
- 3.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.